Last reviewed · How we verify
Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons
To determine the tolerability and immunogenicity of FLUVAL P monovalent influenza vaccine in adults and elderly people, with the objective to verify efficacy and tolerability of the study drug.
Details
| Lead sponsor | Fluart Innovative Vaccine Ltd, Hungary |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 355 |
| Start date | 2009-08 |
| Completion | 2010-02 |
Conditions
- Influenza
Interventions
- Vaccination with Fluval P and Fluval AB influenza vaccines
- Vaccination with Fluval P monovalent influenza vaccine
Primary outcomes
- Post vaccination HI antibody titer — 21-28 days after vaccination
- Incidence of adverse reactions — 21-28 days after vaccination
Countries
Hungary